YOLFTbeta
Abera Bioscience AB

Abera Bioscience AB

ABERA · ST · Healthcare / Biotechnology

7.30SEK+0.04 (+0.55%)

Price History

Full chart

Market Stats

Previous Close7.26
Open7.44
Day Range7.30 – 7.44
52-Week Range5.15 – 10.05
Volume9.63K
Market Cap147.20M
P/E (TTM)0.00
Forward P/E0.00
EPS-0.42
Dividend Yield0.00%
Beta0.63
50-Day Avg7.96
200-Day Avg7.24

About

Abera Bioscience AB, a platform and vaccine development company, research, design, and develops vaccines and immunotherapies based on its proprietary vaccine delivery platform in Sweden and internationally. The company's development platform named BERA, uses for the display of antigens at the surface of outer membrane vesicles derived from genetically optimized gram-negative bacteria. Its lead vaccine candidate is a universal pneumococcal vaccine based on the platform BERA. The company also develops projects in immuno-oncology, Chlamydia, ETEC, Covid-19, and Tuberculosis. The company was incorporated in 2012 and is based in Uppsala, Sweden.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMs. Maria Alriksson
  • Employees5
  • HeadquartersVirdings allé 32, Uppsala, Sweden, 754 50, Sweden
  • Websitehttps://aberabio.com

Leadership

  • Mr. Anders EricssonExecutive Chairman of Board · b. 1970
  • Ms. Maria AlrikssonChief Executive Officer · b. 1983
  • Associate Prof. Joen LuirinkCo-Founder & CTO · b. 1960
  • Mr. Mats LundgrenVP of Research & Development and CSO · b. 1963

Financials

Income Statement

Currency: SEK2022-12-312023-12-312024-12-312025-12-31
Total Revenue0000
Operating Income-19.45M-16.92M-1.34M-10.61M
EBITDA-19.38M-16.72M-1.04M-10.26M
Net Income-19.38M-16.72M-1.10M-10.45M
Interest Expense001.00K0

Balance Sheet

Currency: SEK2022-12-312023-12-312024-12-312025-12-31
Total Assets19.57M9.35M13.60M28.57M
Total Liabilities2.80M3.69M4.95M9.28M
Total Equity16.78M5.66M8.66M19.29M
Cash15.43M3.32M6.09M23.49M

Cash Flow

Currency: SEK2021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow--19.69M-17.71M-198.00K-3.26M
Capital Expenditure0001.13M426.00K
Free Cash Flow--19.69M-17.71M-1.33M-3.68M
FCF to OCF-100.00%100.00%671.21%113.08%

Earnings

Report DateMar 31, 2021Jun 30, 2021Sep 30, 2021Mar 31, 2022Aug 31, 2022Nov 30, 2022Feb 21, 2023May 11, 2023Aug 16, 2023Nov 14, 2023Feb 9, 2024May 14, 2024Aug 21, 2024Nov 12, 2024Feb 13, 2025May 30, 2025Aug 21, 2025Nov 14, 2025Feb 13, 2026May 29, 2026Aug 20, 2026
EPS Estimate-----------0.38-0.140.02-0.17-------
EPS Actual-0.23-0.21-0.18-0.35-0.58-0.36-0.38-0.34-0.44-0.29-0.17-0.02-0.04-0.020.010.00-0.05-0.05-0.47-0.28-0.27
Surprise----------55.26%85.71%-300.00%88.24%-------
Timing----------Pre-marketPre-marketPre-marketAfter-hours-------

Key Statistics & Ratios

Market Cap147.20M
Enterprise Value136.35M
Trailing P/E0.00
Forward P/E0.00
Price / Sales16.18
Price / Book8.59
EPS-0.42
Book Value0.874
Revenue (TTM)9.10M
Gross Profit (TTM)9.10M
EBITDA-21.00M
Profit Margin-230.74%
Operating Margin-360.01%
Return on Equity-163.38%
Return on Assets-72.92%
Shares Outstanding21.46M
Shares Float19.54M
Beta0.63
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%